On-X Life Technologies to Highlight

Reduced Anticoagulation Study Results, Long-Term and Patient Survival Data with the On-X heart valve at STS Meeting Interim results for PROACT Trial, two ten-year clinical research reports and several clinical reports indicating longer survival for mechanical valve patients available to surgeons at The Society of Thoracic Surgeons Meeting AUSTIN, TX – January 24, 2012 – […]

Landmark Clinical Research

Research with the On-X Heart Valve in a poorly anticoagulated South African patient group to be presented at major US Heart Centers Mervyn A. Williams, M.D., of Provincial Hospital in Port Elizabeth, South Africa, to present findings showing that the On-X valve may be able to adapt to fluctuations in anticoagulation with all types of […]

Enrollment Objective Achieved

FDA-approved PROACT (Prospective Randomized On-X Anticoagulation Trial) expects to complete enrollment for all patient groups in 2011 AUSTIN, TX — July 26, 2011 — On-X® Life Technologies, Inc. (On-X LTI) announced today that the enrollment objective for the Low-Risk Aortic Valve Patient Group has been achieved. The Prospective Randomized On-X Valve Anticoagulation Trial (PROACT) was […]

Highlighting 15 Years of Implant Excellence

At the EACTS meeting in Lisbon, Portugal Two ten-year clinical research reports present evidence of continuing superior performance of the On-X® Prosthetic Heart Valve in diverse European and South African patient groups AUSTIN, TX — July 26, 2011 — On-X® Life Technologies, Inc. (On-X LTI) announced today that it is highlighting two clinical studies completed […]

On-X Heart Valve’s Exceptional Clinical Performance

Important Clinical Research Featuring the On-X Heart Valve to be Presented at The Biennial Meeting of the Society for Heart Valve Disease in Barcelona, Spain AUSTIN, Texas, Jun 27, 2011 (BUSINESS WIRE) — On-X(R) Life Technologies, Inc. (On-X LTI) announced today that four clinical trial reports, documenting the On-X(R) Prosthetic Heart Valve’s extraordinary performance, will be presented at the upcoming meeting of the Society for Heart Valve Disease in Barcelona, Spain being held June 25-28, 2011. The reports will include interim clinical results from the Prospective Randomized On-X Anticoagulation Clinical Trial (PROACT), which is being conducted in 36 major institutions in the United States, a comparison of the On-X heart valve with three competitive mechanical valves in Australia, a Ten-year Multiple Center European Study and a Ten-year Study in Poorly Controlled Anticoagulated Patients in South Africa

On-X Heart Valve PROACT Trial Report

On-X Heart Valve PROACT Trial Preliminary Report Provides Evidence toward Maintaining Patients with Less Warfarin Preliminary Results of FDA-Approved PROACT Trial show the On-X® Valve continues to demonstrate tolerance of low INR seen in worldwide studies AUSTIN, TX — April 06, 2011 — On-X® Life Technologies, Inc. announced today that preliminary results from a Food […]

On-X Heart Valve Shows Safety with Reduced Blood Thinners

On-X Heart Valve Shows Safety with Reduced Blood Thinners Early Data Reported From Large FDA IDE Clinical Trial is Encouraging New Orleans, LA — April 5, 2011 – Patients with a mechanical heart valve need lifelong treatment with blood-thinning drugs like warfarin − anticoagulants that prevent blood from clotting on the man-made material but also […]

On-X LTI to Host Satellite Symposium

On-X LTI to Host Satellite Symposium at Society of Thoracic Surgeons (STS) Meeting New Considerations for Prosthetic Valve Choice” challenges current prosthetic heart valve trends AUSTIN, TX — January 25, 2011 — On-X® Life Technologies, Inc. (On-X LTI) announced today that it will host a Satellite Symposium during the Society of Thoracic Surgeons meeting in […]

On-X LTI Receives FDA Approval for AAP

On-X LTI Receives FDA Approval for Aortic Valve with Vascutek Graft Innovative On-X aortic valve is now available with market-leading pre-attached Gelweave Valsalva™ Vascular Prosthesis AUSTIN, TX — January 21, 2011 — On-X® Life Technologies, Inc. (On-X LTI) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market […]

On-X Heart Valve Superior Performance

Large Canadian Heart Valve Study Provides Evidence of On-X® Heart Valve Superior Performance AUSTIN, TX — December 13, 2010 — On-X® Life Technologies, Inc. (On-X LTI), today announced the publication of results of a large, prospective multi-center Canadian trial with the On-X Prosthetic Heart Valve in the November issue of The Journal of Thoracic and […]

Onxlti Responsive Menu
Menu